Showcasing the Next Generation of Oncolytic Viruses

In its most exciting year yet the field of oncolytic virotherapy has seen the highest number of clinical read-outs, the emergence of next generation viruses, and never-before-seen combination therapies.  

Now in its 6th year, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With 3 days of in-depth cutting-edge case studies and the highest calibre of industry discussions, The OV Summit will provide the roadmap to oncolytic virotherapy market success. 

Uncover fresh studies from pharma and biotech companies of all sizes, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities.  

Companies Who Have Joined Us in the Past:

Takeda_logo_logotype
Pfizer_(2021)
AstraZeneca-Logo.wine
Bristol-Myers_Squibb_logo_(2020).svg
192-1921487_bluebird-bio-bluebird-bio-inc-logo
Genentech.svg
800px-AbbVie_logo.svg
Astellas_logo_logotype
1280px-Merck_Logo.svg
1200px-Boehringer_Ingelheim_Logo.svg
Bayer-Logo.wine
amgen
Janssen_Pharmaceuticals_logo.svg

This year’s Summit will help you to: 

  • Understand how viral backbone modification can achieve intravenous delivery 
  • Harness carefully selected payloads to achieve systemic effects  
  • Scale virus production for commercialization 

This year, over 100+ drug developers will converge at the OV Summit to disseminate the latest findings, build a comprehensive network of like-minded peers who share the same challenges and search for the latest combination and genetic engineering strategies. 

Join the leading minds in oncolytic virus development to optimize the development of viral immunotherapies and improve patient outcomes in combination therapies. 

World-Class Speaker Faculty Includes:

Christophe Queva

CSO

Oncorus

Natalia Ulyanova

Director Oncology Business Development

Astellas Pharma

Natalie Roy D’Amore

Director, Partnerships

Takeda Oncology

Nigel Pheasey

Director, Process Development

Amgen

Robert Coffin

CEO

Replimune

Angelica Loskog

CSO

Lokon Pharma

Antonio Chiocca

Neurosurgeon-in- Chief and Chairman, Department of Neurosurgery

Brigham & Women’s Hospital

Paola Grandi

CSO

CG Oncology

Steve Thorne

CSO

KaliVir Immnuotherapeutics

Steven H. Bernstein

Chief Translational Officer

Turnstone Biologics

The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*. For further information around Health and Safety onsite, please visit our FAQ here.

*Please note, this is subject to change at any time without prior notice.

Proud to Partner With:

Expertise Partners

Data Partner

Exhibitor